StickIt Technologies Advances Corporate Strategy with New CEO, Board Members, Debt Restructuring, and IP Portfolio Expansion

VANCOUVER, BC — September 17, 2026 — StickIt Technologies Inc. (TSXV: STKT), a developer and patent holder specializing in cannabinoid and plant extract delivery technologies, today announced significant corporate developments encompassing leadership appointments, financial restructuring, and intellectual property advancements.

Effective July 10, 2026, Dr. Adi Zuloff-Shani assumed the role of Chief Executive Officer, succeeding Eli Ben-Haroosh who resigned on April 1, 2026. Dr. Zuloff-Shani brings over 20 years of executive leadership experience in biotechnology and pharmaceutical sectors, with a strong background in therapeutic research and development. She currently serves as CEO of Clearmind Medicine (CMND), overseeing the development of non-hallucinogenic psychedelic-derived treatments for mental health and addiction disorders. Her expertise spans drug discovery, chemistry, manufacturing and controls (CMC), preclinical and clinical development, and global regulatory strategy.

Concurrently, StickIt expanded its Board of Directors by appointing Mr. Gabriel Kabazo and Mr. Nir Eliyahu as independent, non-executive directors, effective July 10, 2026. These appointments replace all previous directors except Chair Ohad David. Mr. Kabazo is a seasoned finance and operations executive with over 25 years of experience supporting accounting, financing, and IT operations in complex corporate environments. He currently holds CFO or CEO positions at multiple public companies listed on the TSX Venture Exchange, Canadian Securities Exchange, and U.S. markets, bringing extensive expertise in public company reporting, financings, and governance.

Mr. Eliyahu is a private business owner with nine years of experience in distribution channels and online sales, having worked with Connect Inc. (USA) and Telem Distribution in Vancouver. He has been responsible for building B2B and B2C distribution channels, brand development, marketing, sales strategies, and training platforms. Mr. Eliyahu holds a Bachelor of Science degree in Electrical Engineering from the University of Ariel.

Chair of the Board Ohad David commented, "We are thrilled to welcome Dr. Adi Zuloff-Shani as our CEO and expand our Board with seasoned independent directors like Mr. Kabazo and Mr. Eliyahu. These appointments mark a critical milestone in sharpening our strategic execution, enhancing board independence, and driving sustainable shareholder value."

On the financial front, StickIt has completed key recapitalization and financing milestones aimed at optimizing its balance sheet, reducing direct debt obligations, and funding ongoing operations and commercial activities. These efforts build on prior announcements dated October 25 and 29, 2025; December 31, 2025; and February 17, 2026.

As part of its debt restructuring, the company executed transactions under a letter of intent with Capitalink Ltd. (“Capitalink”), whereby Capitalink acquired rights to approximately $617,000 in outstanding debt previously owed by StickIt to corporate insiders, including executive directors. The debt was restructured for a consideration of $380,000. This loan assignment, conducted directly between Mr. Eli Ben-Haroosh, Mr. Asher Holzer, and Capitalink without StickIt as a party, substantially alleviates short-term liability pressures and simplifies the company's debt structure without triggering a fundamental change of corporate control.

Furthering its financial stabilization, StickIt closed a non-brokered private placement offering, issuing 28,884,000 units at CAD $0.025 per unit, raising gross proceeds of CAD $722,100. Each unit comprises one common share and one transferable common share purchase warrant exercisable at CAD $0.025 for 36 months post-closing. To support capital restructuring, StickIt completed a share consolidation on a 1-for-5 basis to increase equity structuring flexibility. The company operated under Canadian Securities Exchange policy exemptions for issuers facing financial difficulty to facilitate the capital injection efficiently.

Net proceeds from the private placement are allocated towards working capital, joint-venture setup costs, raw material procurement, and scaling commercial production of StickIt's flagship "Cannabis Sticks" product lines.

In intellectual property developments, StickIt continues to enforce and expand its competitive advantage through a robust global IP strategy centered on its novel, patent-protected delivery vehicles for therapeutic compounds, plant extracts, and cannabinoid systems. The core IP portfolio includes proprietary "Plant Extracts and Therapeutic Compounds in Smoking Utensils and in Honey Complexes," covering methods and utensils for administering controlled amounts of plant extracts via smoking, as well as complexes combining honey and plant extracts.

Notably, StickIt holds a granted United States patent (US11582996 B2) protecting its therapeutic plant extract delivery devices and specialized smoking utensil inserts, reinforcing its position in the cannabinoid delivery technology market.